| http://www.w3.org/ns/prov#value | - midnormal ranges.[40] The use of anti-CD33/calicheamicin monoclonal antibody (gemtuzumab ozogamicin) as a single agent resulted in 91% (9 of 11 patients) molecular remission after two doses and in 100% of patients (13 of 13) after three doses, thus demonstrating excellent activity of this agent in relapsed APL.[41] Gemtuzumab ozogamicin is currently not available in the United States, except for c
|
